NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Bioverativ Inc. (NASDAQ:BIVV) stockholders concerning the proposed acquisition of the company by Sanofi (NYSE:SNY)
Our investigation concerns whether Bioverativ’s board of directors failed to adequately shop the company and obtain the best possible value for its stockholders before entering into a definitive merger agreement with Sanofi. Under the terms of the agreement, Bioverativ stockholders will receive $105 per share in cash upon closing of the transaction.
If you own Bioverativ shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation of Bioverativ Inc., please go to http://www.bespc.com/bioverativ. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.